P ercutaneous transluminal coronary angioplasty (PTCA) is an effective method of treating patients with symptomatic coronary artery disease.' PTCA achieves vessel dilataton, including both plaque rupture and lumen iexpansion, by stretching the to abrupt closure.3 Numerous studies have documented the role of cyclooxygenase-derived eicosanoids in defining the events before and after PTCA-induced coronary vascular injury.3-6 For example, thromboxane generation by activated platelets and during PTCA is inhibited by aspirin (ASA) and is responsible for vasoconstriction both at the site of arterial injury and distally at the level of the coronary arterioles, sites that control coronary vascular resistance.3-6 However, a significant amount of PTCA-induced vasospasm and platelet aggregation occurs in patients treated with ASA in doses that inhibit cyclooxygenase and thromboxane formation. Fischell et a17 showed that spontaneous vasoconstriction after PTCA in humans occurred routinely at and distal to the site of balloon dilatation despite pretreatment with ASA. Likewise, restenosis after PTCA has not been shown to be altered with ASA.8 9 These findings suggest that substances not inhibited by ASA may play an important role in vasospasm, thrombosis, and accelerated atherosclerosis associated with plaque rupture.
Lipoxygenase (LO)-derived eicosanoids (i.e., peptidoleukotrienes and lipoxins) have proved to be potent vasoactive products whose formation is not inhibited by ASA.10 11 Peptidoleukotrienes (LTs) (LTC4 and LTD4) generated via the 5-LO system are vasoconstrictors of both coronary and cerebral arteries,12,'3 act to decrease cardiac output,14 and promote vascular permeability. 15 Members of the lipoxin series display both unique structures and actions and can be generated either by individual cell types or via transcellular routes of metabolism (Reference 16, recently reviewed in Reference 17) . Lipoxin A4 (LXA4) provokes changes in microcirculation with arteriolar dilatation18"9 and prostanoidindependent dilatation of cerebral arterioles.20 It also stimulates the formation of prostacyclin by human endothelial cells21 and possesses counterregulatory properties. 22 areas beneath each of these peaks were determined by integration using 59970A HP Chemstation software. In this GC system the PFB ester/TMS ether derivatives are well resolved with baseline separation of authentic standards. The PFB ester/TMS ether derivative of LXA4 elutes %7.8-8.0 minutes before the co-20-hydroxy-LTB4 derivative. Likewise, the 5S,12S-DiHETE derivative elutes --0.5-1.6 minutes before the LTB4 PFB ester/TMS ether derivative. For quantitation, standard curves were constructed using the eicosanoids and their respective deuterated internal standards. Linear regression analysis gave correlation coefficients of r=0.99 (LXA4) and r=0.95 (TXB2). The minimum limits of detection were ':74.0+14.1 pmol for LXA4 and =114.9+25.9 pmol for TXB2. Recovery from the combined plasma plus packed cell fractions after NICI SIM was 93.4+4.8% for 2H4-TXB2 and 88.6+3.4% for LXA4 (internal standards). These values were consistent with those recently determined with samples from Peptidoleukotrienes (LTC4, LTD4, and LTE4) were separated and quantitated after 18C solid-phase extraction using RP-HPLC.31 34 This HPLC system was calibrated using the retention times of synthetic LTC4, LTD4, and LTE4, and their quantities were determined by comparing peak areas obtained for calibrated standards. In addition, fractions (1 ml) from this HPLC were collected, dried under vacuum at 23°C, and suspended in phosphate buffer (200 ,ul of 10 mM solution, pH 7.4) containing 0.9% NaCI, 0.1% gelatin, 0.01 M EDTA, and 0.1% sodium azide for quantitation by radioimmunoassay (NEN, Boston).
Ex Vivo Analysis Within a Gore-tex System
Fresh peripheral blood was obtained from healthy volunteers (ages, 18-35 years) who denied taking ASA or other medications for at least 2 weeks before venipuncture. Venous blood (-90 ml) was collected with heparin (500 units/ml). Aliquots (10 ml) were infused into nonendothelialized Gore-tex grafts (3 mmx30 cm, Gore+Assoc., Wakefield, Mass.) and equilibrated at 37°C. Into each graft, a 7F balloon catheter (Mansfield Scientific, Inc., Flagstaff, Ariz.) was inserted and inflated to 7 atm for 10 seconds, and samples were removed through the balloon catheter into a syringe containing indomethacin and esculetin (as above). Incubations were also carried out with injections of selected stimuli (10 min, 37°C). All samples were placed on ice, and eicosanoids were extracted and quantitated as above. Statistics Levels of significance, p, of the differences between ASA and untreated groups were calculated with a paired Student's t test. Values of p<0.05 were considered statistically significant.
Results

Patients
Twelve patients (mean age, 61 years; range, 40-78 years) underwent PTCA. There were no apparent differences with respect to either age, sex, prevalence of diabetes, previous myocardial infarction, distribution of coronary artery disease, or concomitant cardiac medications between the ASA-and non-ASA-treated groups (Table 1) . No complications were encountered during PTCA. Angiography of the target coronary artery immediately after postdeflation sample acquisition showed no significant residual stenosis with normal contrast run-off.
Representative SIM NICI-GC/MS chromatograms obtained for the quantitation of the PFB ester/TMS ether derivatives are given in Figure 1 History of tobacco use (n) 8 4 4 Diabetes (n) 4 2 2 Previous MI (n) 6 3 3 Positive ETT (n) 12 6 6 NYHA (mean±SD) Table 2 reports the levels of individual eicosanoids from ASA-treated and -untreated patients. Intracoronary samples taken before the balloon inflation proximal to the site of the plaque had no detectable amounts of LO-derived eicosanoid in any of the 12 samples. In three of the 12 patients, additional samples were taken distal to the atherosclerotic plaque immediately before balloon inflation. These included one from the ASA group and two from the untreated group. In each of these samples, no detectable quantities of LO products were measured (data not shown). Also, there were no detectable levels of TXB2 in the intracoronary samples taken before balloon inflation. In contrast, the post-PTCA samples taken primarily distal to the site of the plaque obtained from all subjects gave detectable amounts of each of the eicosanoids examined; LTE4, however, was not found in any samples (data not shown). Elevated levels of LO-derived products were obtained from samples from ASA-treated subjects compared with those obtained from the non-ASA-treated group (Table 2) . TXB2 was not detected in samples from the ASA-treated group, which can be taken as an index of cyclooxygenase inhibition.
To assess the potential contribution of whole blood in the production of eicosanoids after angioplasty, we monitored the generation of these products in nonendothelialized Gore-tex grafts filled with blood taken from healthy donors and subjected to either balloon inflation or leukocyte-and/or platelet-directed agonists (Table 3) . Eicosanoids were not detected in samples in which anticoagulated whole blood was incubated within Gore-tex graft without stimuli or mechanical manipulation (data not shown). As expected, upon injection of thrombin, TXB2 was generated. On the other hand, LXA4, 5S,12S-DiHETE, and the peptidoleukotrienes were produced only when the samples were exposed to both thrombin and the chemotactic peptide formylmethionyl-leucine-phenylalanine.
Balloon inflation did not lead to the generation of detectable levels of 5S,12S-DiHETE in Gore-tex grafts ( Table 3 ), suggesting that these two forms of activating components of whole blood (balloon inflation versus selected stimuli) are not comparable. Addition of the ionophore A23187 (5 ,M) to whole blood ex vivo gives a TXB2:LXA4 ratio of M3:1, which is comparable to thrombin (1.0 IU), albeit the levels are :4 times lower.28 When isolated whole blood is incubated with A23187 (25 ,uM), evidence for only small amounts of 5S,12S-DiHETE has been presented compared with the levels of LTB4 generated in the incubations as monitored by HPLC. 37 The ionophore A23187 is a powerful stimulus for LTB4 production in whole blood37 that bypasses receptor ligand activation. Thus, it appears that the profile and quantitative relation between eicosanoids generated is dependent not only on the stimulus or agonist but also on the cell types and materials present in the local milieu.
Discussion
In this paper, we report the intracoronary identification of LO-derived eicosanoids after plaque rupture induced by PTCA. Samples taken before balloon inflation that were immediately proximal to a stenosis did not reveal the presence of these eicosanoids. They were also not detected in samples from three individuals taken immediately distal to the site of the atherosclerotic plaque. In contrast, those taken distal to the plaque site after PTCA contained LO-derived eicosanoids, i.e., LXA4, LTC4, LTD4, and 5S,12S-DiHETE (Table 2 ). In addition, patients undergoing ASA therapy had significantly higher levels of LTC4 and LTD4. These results are the first to document intracoronary levels of LO-derived eicosanoids and the impact of ASA therapy. Moreover, they provide direct evidence for the presence of LXA4 and 5S,12S-DiHETE within a human vessel ( Figure 1 , Table 2 ), both of which are potential products of transcellular eicosanoid metabolism in human tissues. 24 15 20 TIME (min) from 1) the atherosclerotic plaque itself, 2) the interaction of the released plaque debris with peripheral blood cells, and/or 3) activation of the peripheral blood by the PTCA, percutaneous transluminal coronary angioplasty; LT, leukotriene; ND, not detected. All results are expressed as ng/ml intracoronary sample. Samples were collected immediately before and 10 seconds after balloon inflation into syringes containing heparin (500 units/ml), esculetin (400 ,uM), and indomethacin (400 ,uM) and placed on ice. Results represent mean+SEM of n=6 from each treatment group. *p<0.05 compared with no aspirin group. A4; TXB2, thromboxane B2; 5S,12S-DiHETE, 5S,12S-dihydroxy-6,8,10,14-eicosatetraenoic acid; LT, leukotriene; ND, not detected; fMLP, formylmethionyl-leucine-phenylalanine. Values are expressed as ng/ml sample.
Fresh whole blood was collected by use of heparin and suspended within the Gore-tex grafts (3 mmx30 cm).
Incubations (10 ml) of whole blood were kept at 37°C in the Gore-tex grafts 1) before insertion of angioplasty balloon,
2) before injection of stimuli, or 3) incubated alone (control). Results represent mean±SEM of n=3 different donors with duplicate determinations in each.
balloon catheter. The absence of detectable quantities of LO-derived products before balloon inflation does not preclude the possible existence of either leukotrienes or lipoxins generated locally distal to the stenosis before angioplasty. Although the origin(s) of production and/or liberation of these LO products cannot be shown conclusively from the present results, recent evidence suggests that the cellular components of atherosclerotic plaques can generate LO-derived products. Monocytes In a second group of experiments to address this, balloon inflation into Gore-tex grafts filled with whole blood failed to generate detectable quantities of LOderived eicosanoids (Table 3 ). This finding also suggests the participation of the atherosclerotic plaque. Thus, the appearance of LO-derived eicosanoids within the coronary artery may involve either 1) release of preformed eicosanoids or their precursors liberated from the plaque into blood during plaque rupture or 2) direct activation of peripheral blood components (i.e., platelets and neutrophils) by compounds or debris released from the plaque. Together, the results in Table 3 suggest that balloon inflation can stimulate TXB2 production, presumably by mechanical activation of platelets, a finding consistent with a previous report.6 However, balloon inflation within Gore-tex grafts itself failed to generate peptidoleukotrienes, LXA4, and 5S,12S-DiHETE in these samples, suggesting that the atheroma may participate in the production of LO-derived eicosanoids immediately after PTCA.
5S,12S-DiHETE is structurally similar to LTB4 in that it is a 5,12-dihydroxy acid.24 25 Unlike LTB4, however, it is not derived from the epoxide LTA4 but is generated 37 These results suggest that if LTB4 is generated or liberated during plaque rupture, it may not be subject to w-oxidization in the intracoronary milieu. LTB4 was not quantitated in the present study; thus, its possible presence in the intracoronary milieu after plaque rupture awaits future studies.
The mass ratio of LXA4 to peptidoleukotrienes appears to favor LXA4. In addition, peptidoleukotrienes were elevated in a statistically significant fashion after ASA therapy ( In the current study, we examine the intracoronary appearance of lipoxin A4, thromboxane B2, peptidoleukotrienes, and 5S,12S-DiHETE before and after PTCA. A complete profile of eicosanoids and their temporal relation would be insightful as to the relative production of the individual products. Here, we limited the measurements to selected representatives shown to be vasoactive compounds from the lipoxygenase pathways. Further studies will widen the scope of other eicosanoids that may be generated by the atherosclerotic plaque. In summary, the present results demonstrate the appearance of LO products after plaque rupture and that increases in these products can occur in vivo with ASA therapy. They are also the first to identify putative products of transcellular eicosanoid metabolism in vivo. These results implicate the participation of atherosclerotic plaques or possible plaque-derived materials interacting with blood cells in the production of LO-derived eicosanoids. Taken together, they add to the complex repertoire of events that occurs after PTCA. Moreover, these findings suggest that pharmacological interventions both at the level of leukotriene inhibitors and receptor level antagonists may be useful in the prevention of PTCA-associated complications.
Note added in proof Recent results from Salbach et a149 demonstrate that low density lipoproteins (LDL) can provide arachidonic acid for eicosanoid generation by activated monocytes in vitro. In view of our results, the conversion of LDL-derived arachidonic acid into lipoxygenase products49 may also contribute to the mechanisms leading to leukotriene and lipoxin release after PTCA.
